• 1
    Brabin BJ. 1991. The risks and severity of malaria in pregnant women. Applied Field Research in Malaria Reports, No. 1. UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases (TDR), Geneva , Switzerland .
  • 2
    World Health Organization. International Travel and Health. Geneva : World Health Organization, 1995.
  • 3
    Nathwani D, Currie PF, Douglas JG, et al. Plasmodium falciparum malaria in pregnancy: a review. Br J Obstet Gynaecol 1992; 99:118121.
  • 4
    Steffen R, Fuchs E, Schildknecht J, et al. Mefloquine compared with other malaria chemoprophylactic regimens in tourists visiting East Africa. Lancet 1993; 341:12991303.
  • 5
    Lobel HO, Miani M, Eng T, et al. Long-term malaria prophylaxis with weekly mefloquine. Lancet 1993; 341:848851.
  • 6
    Greenwood B, Greenwood AM, Snow RW, et al. The effects of malaria chemoprophylaxis given by traditional birth attendants on the course and outcome of pregnancy. Trans R Soc Trap Hyg 1989; 83:589594.
  • 7
    Nosten F, Ter Kuile F, Maelankiri L, et al. Mefloquine prophylaxis prevents malaria during pregnancy: a double-blind, placebo-controlled study. J Infect Dis 1994; 169:595603.
  • 8
    Steketee RW, Wirima JJ, Khoromana CO, et al. Malaria prevention in pregnancy: the effects of treatment and chemoprophylaxis on placental malaria infection, low birth weight, and fetal, infant, and child survival. United States Agency for International Development Africa Regional Project (698–0421), U.S. Department of Health and Human Services.
  • 9
    Schultz LJ, Steketee RW, Macheso A, et al. The efficacy of antimalarial regimens containing sulfadoxine-pyrimethamine and/or chloroquine in preventing peripheral and placental Plasmodium falciparum infection among pregnant women in Malawi. Am J Trop Med Hyg 1994; 51:515522.
  • 10
    Reynolds J. Martindale. The extra pharmacopia. 29th Ed. London : Pharmaceutical Press, 1989.
  • 11
    Kato T, Kitagwa S. Production of congenital abnormalities in fetuses of rats and mice with various sulfonamides. Congenital Anomalies 1973; 13:713.
  • 12
    Thiersch JB. Effects of certain 2,4-diaminopyrimidine antagonists of folic acid on pregnancy and rat fetus. Proc Soc Exp Biol (NY) 1954; 87:571577.
  • 13
    Walter Reed Army Institute for Research. Appendix E. Mefloquine. Background Information. New Drug Application to the US Food and Drug Administration (unpublished). Washington , USA : Walter Reed Army Institute of Research, 1986.
  • 14
    Mimica I, Fry W, Eckart G, Schwardt DE. Multiple dose kinetic study of mefloquine in healthy male volunteers. Chemother 1983; 27:184187.
  • 15
    Nosten F, et al. Mefloquine antimalarial prophylaxis in pregnancy: dose finding and pharmacokinetic study. Br J Clin Pharmacol 1990; 30:7985.
  • 16
    Gustafsson LL, Walker O, Alvan G, et al. The disposition of chloroquine in man after single intravenous and oral doses. Br J Clin Pharmacol 1983; 15:481489.
  • 17
    Gilman AG, Goodman LS, Gilman A. The pharmacological basis of therapeutics. 6th Ed. New York : Macmillan, 1980:1049.
  • 18
    Wangboonskul J, White NJ, Nosten F, et al. Single dose pharmacokinetics of proguanil and its metabolites in pregnancy. Eur J Clin Pharmacol 1993; 44:247251.
  • 19
    Kline J, Stein Z, Susser M. Conception to birth: epidemiology of prenatal development. Monographs in epidemiology and biostatistics. Vol. 14. New York : Oxford University Press, 1990.
  • 20
    Heinonen OP, Slone D, Shapiro S. Birth defects and drugs in pregnancy. Littleton , Massachusetts : Publishing Sciences Group, Inc., 1977.
  • 21
    Smoake BL, Writer JV, Keep LW. The effects of inadvertent exposure to mefloquine chemoprophylaxis on pregnancy outcomes and infants of US Army service women. J Infect Dis 1997; 176:831833.
  • 22
    Balocco R, Bonati M. Mefloquine prophylaxis against malaria for female travellers of childbearing age. Lancet 1992; 340:309310.
  • 23
    Wolfe M, Cordero J. Safety of chloroquine in chemosup-pression of malaria during pregnancy. BMJ 1985; 190:1466.